S. Shak

发表

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

M. Cronin, S. Paik, G. Tang, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

M. Cronin, S. Paik, G. Tang, 2004, The New England journal of medicine.

First-Line Herceptin® Monotherapy in Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2001, Oncology.

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.

N. Robert, D. Tripathy, S. Shak, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Lyndsay N Harris, L. Harris, S. Shak, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

Andreas Makris, Susan G. Hilsenbeck, Frederick L. Baehner, 2008, Breast Cancer Research and Treatment.

Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

Jack Cuzick, Mitch Dowsett, Michael Baum, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.

Robert B Livingston, Lois Shepherd, James N Ingle, 2010, The Lancet. Oncology.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Roman Rouzier, Lajos Pusztai, J. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

S. Shak, J. Baker, D. Watson, 2006, Breast Cancer Research.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Robert Gray, Sunil Badve, Edith A Perez, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract S1-10: Association between the 21-gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+), ER-positive breast cancer patients (pts): Results from NSABP B-28

T. Julian, S. Paik, G. Tang, 2012 .

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

T. Fleming, L. Norton, J. Baselga, 2001, The New England journal of medicine.

2131 DEVELOPMENT AND VALIDATION OF THE BIOPSY-BASED GENOMIC PROSTATE SCORE (GPS) AS A PREDICTOR OF HIGH GRADE OR EXTRACAPSULAR PROSTATE CANCER TO IMPROVE PATIENT SELECTION FOR ACTIVE SURVEILLANCE

M. Cooperberg, P. Carroll, M. Kattan, 2013 .

Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay.

Debjani Dutta, M. Cronin, S. Shak, 2004, The American journal of pathology.

Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.

Debora Fumagalli, Norman Wolmark, Soonmyung Paik, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Population-based study of hormone receptor status comparing Oncotype DX with standard immunohistochemistry

S. Shak, A. Gown, L. Habel, 2009, Breast Cancer Research.

HER2 assessment using fluorescence in situ hybridization compared with Oncotype DX and association with risk of breast cancer death

S. Shak, A. Gown, L. Habel, 2009, Breast Cancer Research.

Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy

Kevin Coombes, Massimo Cristofanilli, Sang-Joon Lee, 2005, Clinical Cancer Research.

Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis. A phase 1 study.

S. Shak, W. Burke, A. Smith, 1992, JAMA.

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

S. Shak, D. Geddes, M. Hodson, 1993, The Lancet.

Production of chemotactic activity for polymorphonuclear leukocytes by cultured rat hepatocytes exposed to ethanol.

S. Shak, H. Perez, I. Goldstein, 1984, The Journal of clinical investigation.

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer

S. Shak, F. Baehner, N. Harbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrence score and quantitative ER expression to predict in late distant recurrence risk in ER+ BC after 5 years of tamoxifen.

S. Paik, G. Tang, S. Shak, 2014 .

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2011, British Journal of Cancer.

Abstract P4-11-01: Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

S. Shak, N. Harbeck, O. Gluz, 2015 .

Prospective comparison of recurrence score, uPA/PAI-1, central grade and molecular classification in early breast cancer: Interim results from the WSG-Plan B trial.

S. Shak, N. Harbeck, O. Gluz, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Technical Advance Measurement of Gene Expression in Archival Paraffin-Embedded Tissues Development and Performance of a 92-Gene Reverse Transcriptase-Polymerase Chain Reaction Assay

M. Cronin, S. Shak, J. Baker, 2003 .

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.

S. Shak, N. Harbeck, O. Gluz, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the 12-gene colon cancer recurrence score in NSABP C-07 as a predictor of recurrence in patients with stage II and III colon cancer treated with fluorouracil and leucovorin (FU/LV) and FU/LV plus oxaliplatin.

Margarita Lopatin, Greg Yothers, Carl Millward, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of a 12-gene colon cancer recurrence score (RS) in patients (pts) with stage II colon cancer (CC) from CALGB 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular Characterization and Mortality From Breast Cancer in Men.

G. Sledge, S. Shak, Dave P. Miller, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast

George W. Sledge, David L. Page, Robert Gray, 2013, Journal of the National Cancer Institute.

Quantitative gene expression analysis using Oncotype DX in ductal carcinomain situthat is adjacent to invasive ductal carcinoma.

S. Shak, F. Baehner, A. Goddard, 2009 .

Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.

R. Gray, E. Perez, G. Sledge, 2012 .

S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.

R. Gray, G. Sledge, S. Shak, 2011 .

Abstract S5-04: A large prospectively-designed study of the DCIS score: Predicting recurrence risk after local excision for ductal carcinoma in situ patients with and without irradiation

S. Shak, E. Rakovitch, R. Saskin, 2015 .

A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone

S. Shak, F. Baehner, E. Rakovitch, 2015, Breast Cancer Research and Treatment.

A glycan-phosphatidylinositol-specific phospholipase D in human serum.

V. Nussenzweig, S. Shak, P. T. Englund, 1987, Science.

Gene expression profiles of paraffin-embedded core biopsy tissue predict response to chemotherapy in patients with locally advanced breast cancer.

M. Cronin, S. Shak, J. Baker, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel dioxygenation product of arachidonic acid possesses potent chemotactic activity for human polymorphonuclear leukocytes.

S. Shak, H. Perez, I. Goldstein, 1983, The Journal of biological chemistry.

Leukotriene B 4 w-Hydroxylase in Human Polymorphonuclear Leukocytes Partial Purification and Identification as a Cytochrome P-450

S. Shak, 2013 .

The Major Pathway for Leukotriene B4 Catabolism in Human Polymorphonuclear Leukocytes Involves ω-Oxidation by a Cytochrome P-450 Enzyme

S. Shak, I. Goldstein, 1985 .

Carbon monoxide inhibits omega-oxidation of leukotriene B4 by human polymorphonuclear leukocytes: evidence that catabolism of leukotriene B4 is mediated by a cytochrome P-450 enzyme.

S. Shak, I. Goldstein, 1984, Biochemical and biophysical research communications.

Prostaglandin I2 is not a major metabolite of arachidonic acid in cultured endothelial cells from human foreskin microvessels.

S. Shak, I. Charo, I. Goldstein, 1984, The Journal of clinical investigation.

Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

S. Shak, 1999, Seminars in oncology.

Prognostic Role of aMultigene ReverseTranscriptase-PCRAssay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant

K. Coombes, G. Hortobagyi, M. Cronin, 2005 .

Gene expression and breast cancer mortality in Northern California Kaiser Permanente Patients: A large population-based case control study

S. Shak, J. Baker, D. Watson, 2005 .

Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Suicidal inactivation by acetylenic fatty acids.

P. Ortiz de Montellano, S. Shak, N. Reich, 1985, The Journal of biological chemistry.

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum.

S. Shak, S. Marsters, D. Capon, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Leukotriene B4 omega-hydroxylase in human polymorphonuclear leukocytes. Partial purification and identification as a cytochrome P-450.

S. Shak, I. Goldstein, 1985, Journal of Clinical Investigation.

Abstract P3-10-01: Quantitative Gene Expression Analysis in a Large Cohort of Estrogen-Receptor Positive Breast Cancers: Characterization of the Tumor Profiles in Younger Patients (≥40 yrs) and in Older Patients (≥70 yrs)

S. Shak, F. Baehner, D. Watson, 2010 .

S4-3: Prospective Comparison of Risk Assessment Tools in Early Breast Cancer (Recurrence Score, uPA/PAI-1, Central Grade, and Luminal Subtypes): Final Correlation Analysis from the Phase III WSG-Plan B Trial.

S. Shak, N. Harbeck, O. Gluz, 2011 .

Risk of distant recurrence using oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study.

J. Cuzick, J. Forbes, M. Dowsett, 2009 .

Leukotriene B4 w-Hydroxylase in Human Polymorphonuclear Leukocytes

S. Shak, 2022 .

Effects of rhDNase on purulent airway secretions in chronic bronchitis.

S. Shak, J. Zahm, S. de Bentzmann, 1996, The European respiratory journal.

Leukotriene B4 catabolism: quantitation of leukotriene B4 and its omega-oxidation products by reversed-phase high-performance liquid chromatography.

S. Shak, 1987, Methods in enzymology.

Prognostic impact of the 21-gene recurrence score (RS) on disease-free and overall survival of node-positive, ER-positive breast cancer patients (pts) treated with adjuvant chemotherapy: Results from NSABP B-28.

T. Julian, S. Paik, G. Tang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the 12-gene colon cancer recurrence score (RS) in NSABP C07 as a predictor of recurrence in stage II and III colon cancer patients treated with 5FU/LV (FU) and 5FU/LV+oxaliplatin (FU+Ox).

S. Paik, S. Shak, N. Wolmark, 2012 .

Evaluation of tumor gene expression and K-Ras mutations in FFPE tumor tissue as predictors of response to cetuximab in metastatic colorectal cancer

S. Shak, J. Baker, D. Watson, 2008 .

Modification of CD4 immunoadhesin with monomethoxypoly(ethylene glycol) aldehyde via reductive alkylation.

S. Shak, M. Venuti, A. Ashkenazi, 1994, Bioconjugate chemistry.

The relationship between quantitative HER2 gene expression by the 21-gene RT-PCR assay and adjuvant trastuzumab (H) benefit in NCCTG (Alliance) N9831.

Y. Asmann, E. Perez, E. Thompson, 2013 .

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Edith A Perez, E. Perez, S. Martino, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

G. Hortobagyi, A. Giuliano, S. Shak, 2022, Annals of Surgical Oncology.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Joseph P. Costantino, Stewart J. Anderson, Norman Wolmark, 2011, Breast Cancer Research and Treatment.

The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone

S. Shak, S. Thiru, D. Sinicropi, 1996, Clinical and experimental immunology.

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.

G. Hortobagyi, L. Pusztai, D. Tripathy, 2021, The New England journal of medicine.

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.

S. Paik, G. Tang, S. Shak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

GRB7-dependent pathways are potential therapeutic targets in triple-negative breast cancer.

R. Gray, S. Martino, G. Sledge, 2009 .

Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.

S. Shak, 1995, Chest.

Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus.

S. Shak, J. Zahm, M. Roussey, 1995, The European respiratory journal.

Dose-dependent in v vitro effect o of rrecombinant h human D DNase o on rheological a and ttransport p properties o of c cystic ffibrosis respiratory m mucus

S. Shak, M. Roussey, A. Dabadie, 1995 .

Coarse spray delivery to a localized region of the pulmonary airways for gene therapy.

R. Crystal, S. Shak, T. Sweeney, 2000, Human gene therapy.

Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ.

S. Shak, F. Baehner, E. Rakovitch, 2017, Journal of the National Cancer Institute.

Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

A. Tucker, R. Crystal, S. Shak, 1999, The Journal of clinical investigation.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

S. Shak, N. Harbeck, O. Gluz, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prediction of recurrence with the Oncotype DX recurrence score in node-positive, HR-positive, breast cancer patients treated with adjuvant chemotherapy: Results from PACS01 trial.

S. Shak, F. Baehner, F. Penault-Llorca, 2014 .

The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831

Y. Asmann, E. Perez, E. Thompson, 2015, Breast Cancer Research.

Spreading of human neutrophils is immediately preceded by a large increase in cytoplasmic free calcium.

S. Shak, F. Maxfield, B. Kruskal, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Cardiac dysfunction in the trastuzumab clinical trials experience.

C. Hudis, S. Shak, M. Murphy, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Partial characterization of the cross-reacting determinant, a carbohydrate epitope shared by decay accelerating factor and the variant surface glycoprotein of the African Trypanosoma brucei.

V. Nussenzweig, S. Shak, M. Turner, 1988, Journal of immunology.

The run-in phase of the prospective WSG-ADAPT HR+/HER2– trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer

S. Shak, F. Baehner, N. Harbeck, 2020, Therapeutic advances in medical oncology.

21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology

T. Julian, S. Paik, G. Tang, 2018, Breast Cancer Research and Treatment.

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

P. Febbo, M. Cooperberg, P. Carroll, 2014, European urology.

Epithelial membrane protein-1 is a biomarker of gefitinib resistance.

S. Shak, D. Agus, Anjali Jain, 2005, Proceedings of the National Academy of Sciences of the United States of America.

Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients.

H. Putter, S. Shak, P. Kuppen, 2014, Journal of the National Cancer Institute.

Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes

M. Cronin, J. Mosquera, S. Shak, 2005, Clinical Cancer Research.

Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue

M. Cronin, G. Sledge, S. Shak, 2007, Breast Cancer Research and Treatment.

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

D. Kerr, S. Shak, F. Baehner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multigene Expression Assay and Benefit of Radiotherapy After Breast Conservation in Ductal Carcinoma in Situ

Rinku Sutradhar, Sharon Nofech-Mozes, Lawrence Paszat, 2017, Journal of the National Cancer Institute.

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

R. Schilsky, M. Bertagnolli, P. Friedman, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leveraging biospecimen resources for discovery or validation of markers for early cancer detection.

B. Kramer, M. Khoury, K. Goddard, 2015, Journal of the National Cancer Institute.

Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories.

L. Goldstein, A. Gown, S. Shak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multi-gene Rt-pcr assay for predicting recurrence in node negative breast cancer patients-nsabp studies B-20 and B-14

Norman Wolmark, Soonmyung Paik, Gong Tang, 2003 .

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.

G. Sledge, S. Shak, R. Benjamin, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes.

S. Shak, I. Goldstein, S Shak, 1984, The Journal of biological chemistry.

Feasibility of using tissue microarray cores of paraffin-embedded breast cancer tissue for measurement of gene expression: a proof-of-concept study

M. Dowsett, S. Shak, F. Baehner, 2010, Journal of Clinical Pathology.

Oncotype DX and proliferation response to short-term preoperative endocrine therapy for chemotherapy decision in early breast cancer: Biomarker data from the prospective multicenter phase II/III WSG-ADAPT trial.

M. Rezai, S. Shak, N. Harbeck, 2014 .

Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer

R. Gray, G. Tang, S. Shak, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

J. Cuzick, J. Forbes, M. Dowsett, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry

S. Shak, T. Peretz, N. Liebermann, 2017, npj Breast Cancer.

Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

S. Shak, N. Harbeck, O. Gluz, 2017, Breast Cancer Research and Treatment.

Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database

S. Shak, Megan C. Roberts, V. Petkov, 2017, Breast Cancer Research and Treatment.

Molecular characterization of male breast cancer by standardized quantitative RT-PCR analysis: First large genomic study of 347 male breast cancers compared to 82,434 female breast cancers.

G. Sledge, S. Shak, F. Baehner, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.

E. Winer, G. Hortobagyi, A. Giuliano, 2021, Journal of the National Cancer Institute.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer.

R. Jagsi, W. Woodward, G. Hortobagyi, 2020, JAMA oncology.

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy

T. Julian, S. Paik, G. Tang, 2017, Journal of the National Cancer Institute.

Herceptin (R) improves time to progression following chemotherapy in women with metastatic breast cancer

B. Leyland-Jones, S. Shak, D. Slamon, 1999 .

Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer

M. Cronin, S. Paik, G. Tang, 2005 .

Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study

R. Gray, E. Perez, S. Martino, 2012, Breast Cancer Research and Treatment.

Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.

S. Paik, S. Shak, J. Baker, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The 12-gene colon cancer assay validation and utility: Summary of clinical evidence.

S. Shak, M. Lopatin, K. Clark-Langone, 2014 .

Y. Asmann, E. Perez, E. Thompson, 2015, Breast Cancer Research.

Ten-year clinical outcomes in N0 ER+ breast cancer patients with Recurrence Score-guided therapy

S. Shak, B. Uziely, D. Katz, 2019, npj Breast Cancer.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

N. Howlader, S. Shak, F. Baehner, 2016, npj Breast Cancer.

from Human Foreskin Microvessels

S. Shak, I. Charo, I. Goldstein, 1984 .

Abstract GS4-03: Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study

R. Gray, J. Cuzick, M. Dowsett, 2020 .

Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011, Clinical Cancer Research.

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

Silvana, R. Gray, E. Perez, 2011 .

Predictive Biomarkers and Personalized Medicine Relationship between Quantitative GRB 7 RNA Expression and Recurrence after Adjuvant Anthracycline Chemotherapy in Triple-Negative Breast Cancer

R. Gray, E. Perez, S. Martino, 2011 .

Addition of Herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anti-cancer activity: a randomised multinational controlled phase III trial

T. Fleming, L. Norton, J. Baselga, 1998 .

Accurate assessment of human epidermal growth factor receptor 2.

S. Shak, F. Baehner, C. Yoshizawa, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

HER2 concordance between central laboratory immunohistochemistry and quantitative reverse transcription polymerase chain reaction in Intergroup Trial E2197

R. Gray, G. Sledge, S. Shak, 2008 .

A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study.

D. Kerr, S. Shak, D. Watson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Concordance of local and central laboratory hormone and HER2 receptor status in ECOG 2197

R. Gray, S. Shak, S. Badve, 2007 .

Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer

R. Gray, E. Perez, S. Martino, 2009, Clinical Cancer Research.

Reply to J.M. Guinebretiere and L. Arnould et al

E. Perez, S. Martino, G. Sledge, 2009 .

Engineering actin-resistant human DNase I for treatment of cystic fibrosis.

S. Shak, K. Toy, R. Lazarus, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje

S. Paik, G. Tang, S. Shak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS4-04: Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: Primary outcome results from the WSG-ADAPT HR+/HER2- trial

M. Hauptmann, S. Shak, N. Harbeck, 2021 .

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

L. Harris, S. Shak, M. Cobleigh, 2001, European journal of cancer.

Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial

F. Feuerhake, S. Shak, N. Harbeck, 2020, Breast Cancer Research.

Abstract P2-10-08: Prospective comparison of Recurrence Score and different definitions of luminal subtypes by central pathology assessment of single markers in early breast cancer: results from the phase III WSG-planB Trial

S. Shak, N. Harbeck, O. Gluz, 2012 .

A Large Prospectively Designed Study of the DCIS Score: Recurrence Risk After Local Excision For Ductal Carcinoma In Situ Patients With and Without Irradiation

S. Shak, E. Rakovitch, R. Saskin, 2015 .

Correlation between the DCIS Score and traditional clinicopathologic features in the prospectively-designed Ontario population-based validation study.

S. Shak, F. Baehner, E. Rakovitch, 2015 .

Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

N. Robert, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies

R. Gray, S. Shak, F. Baehner, 2018, Breast Cancer Research and Treatment.

Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry

S. Shak, B. Uziely, J. Zidan, 2017, npj Breast Cancer.

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial

G. Hortobagyi, L. Pusztai, W. Symmans, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colorimetric determination of DNase I activity with a DNA-methyl green substrate.

S. Shak, D. Sinicropi, D. L. Baker, 1994, Analytical biochemistry.

The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer Treated on SWOG S8814

R. Jagsi, W. Woodward, G. Hortobagyi, 2016 .

A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.

R. Crystal, S. Shak, N. McElvaney, 1992, The New England journal of medicine.

Recurrence risk of node-negative and ER-positive early-stage breast cancer patients by combining recurrence score, pathologic, and clinical information: A meta-analysis approach.

J. Cuzick, J. Forbes, M. Dowsett, 2010 .

Abstract P6-05-11: Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine

M. Rezai, S. Shak, N. Harbeck, 2013 .

Gene expression markers for breast cancer prognosis of

M. Cronin, S. Shak, J. Baker, 2004 .

Molecular Characterization of Breast Cancer Core Biopsy Specimens by Gene Expression Analysis Using Standardized Quantitative RT-PCR.

S. Shak, F. Baehner, D. Watson, 2009 .

Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC→4x doc vs. 6x docetaxel/cyclophosphamide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer.

S. Shak, N. Harbeck, O. Gluz, 2017 .

Prospective comparison of recurrence score and independent central pathology assessment of prognostic tools in early breast cancer (BC): Focus on HER2, ER, PR, Ki-67 results from the phase III WSG-Plan B trial.

S. Shak, N. Harbeck, O. Gluz, 2012 .

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Ennis, Lex, Rian, 2001, The New England journal of medicine.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial)

S. Shak, F. Baehner, F. Penault-Llorca, 2018, BMC Cancer.

The development of the DCIS score: Scaling and normalization in the Marin General Hospital cohort.

S. Shak, S. Butler, C. Yoshizawa, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

N. Howlader, S. Shak, F. Baehner, 2016, npj Breast Cancer.

Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)

N. Howlader, S. Shak, F. Baehner, 2016 .

Re: Breast cancer gene microarrays pass muster.

S. Shak, J. Baker, G. Palmer, 2007, Journal of the National Cancer Institute.

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

S. Paik, G. Tang, S. Shak, 2018, npj Breast Cancer.

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

L. Harris, S. Shak, C. Vogel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer.

D. Kerr, S. Shak, F. Baehner, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential biologic causes of the racial survival disparity in adjuvant trials of ER-positive breast cancer.

G. Hortobagyi, S. Shak, W. Barlow, 2010 .

Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study

N. Howlader, S. Shak, F. Baehner, 2016, npj Breast Cancer.

Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx

G. Hortobagyi, A. Giuliano, S. Shak, 2022, Annals of Surgical Oncology.

Prediction of 10-Year Chemotherapy Benefit and Breast Cancer-Specific Survival by the 21-Gene Recurrence Score (RS) Assay in Node-Positive, ER-Positive Breast Cancer – An Update of SWOG-8814 (INT0100).

E. Winer, E. Perez, G. Hortobagyi, 2009 .

Evaluation of recurrence score and traditional clinicopathologic metrics in a large ER-positive, lymph node-negative patient cohort.

S. Shak, F. Baehner, C. Yoshizawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort.

S. Shak, F. Baehner, C. Yoshizawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.

R. Gibson, S. Shak, S. Astley, 1993, The American review of respiratory disease.

Abstract S4-9: Comparing the Prediction of Chemotherapy Benefit in Patients with Node-Negative, ER-Positive Breast Cancer Using the Recurrence Score and a New Measure That Integrates Clinical and Pathologic Factors with the Recurrence Score

G. Tang, S. Shak, J. Costantino, 2010 .